Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Lymphoma, Non-Hodgkin 4Lymphoma 4Leukemia 4Vomiting 3Neoplasms 3Neoplasm Metastasis 3Multiple Myeloma 3Lymphoma, B-Cell 3Hodgkin Disease 3Breast Neoplasms 3Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Nausea 2Myelodysplastic Syndromes 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Hairy Cell 2Kidney Neoplasms 2Hematologic Neoplasms 2Carcinoma, Renal Cell 2Carcinoma in Situ 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Alveolar Soft Part 1Rectal Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Rituximab 93Cyclophosphamide 72fludarabine phosphate 53Whole-Body Irradiation 43Mycophenolic Acid 40Peripheral Blood Stem Cell Transplantation 39Bortezomib 30Tacrolimus 29Etoposide 29Cyclosporine 28Melphalan 26Filgrastim 26Busulfan 26Methotrexate 24Lenalidomide 23Cytarabine 23ibrutinib 20Vincristine 20Granulocyte Colony-Stimulating Factor 20Antilymphocyte Serum 20Doxorubicin 18Bendamustine Hydrochloride 18Dexamethasone 16Sirolimus 14fludarabine 13Carmustine 13Cord Blood Stem Cell Transplantation 12Calcium Dobesilate 12Radiotherapy 11Prednisone 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Lymphoma, Mantle-Cell × Diphenhydramine × Clear all
NCT04599634 2025-02-04

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
11 enrolled 16 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT00186628 2017-11-28

Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD

Stanford University

Phase 2 Completed
36 enrolled 12 charts
LymphoidOther hematologic neoplasm

Leukemia, Mast-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡